Corrigendum to "Design and development of chromene-3-carboxylate derivatives as antidiabetic agents: Exploring the antidiabetic potential via dual inhibition of angiotensin II type 1 receptor and neprilysin enzyme" [Europ. J. Med. Chem. 293 (2025) 117705]

Eur J Med Chem. 2025 Jun 16:117772. doi: 10.1016/j.ejmech.2025.117772. Online ahead of print.
No abstract available

Publication types

  • Published Erratum